CLIENT-PHARMA LTDActive

Company number 08723939Private limited companyIncorporated 2013
⚠ Confirmation statement overdue. It was due on 17 Oct 2026.

Key figures

£2,525,935+31.3%
Net assets 2025
+20.3%
Average annual growth 2020–2025
01 m2 m3 m20202021202220242025

Like most small UK companies, CLIENT-PHARMA LTD does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.

Ratios

2025
Balance sheet structure
Current assetsFixed assetsLiabilitiesNet assets
02 m4 m6 m20202021202220242025
Filed accounts2020–2025
20202021202220242025
Cash at bank and in hand1,776,7821,601,6781,019,9961,213,8561,935,621
Total assets3,006,0114,182,6402,314,8162,721,5503,896,683
Total liabilities———793,8611,368,186
Net assets / total equity1,206,468750,2541,167,4301,923,9652,525,935
Average number of employees131414160

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Summary: CLIENT-PHARMA LTD

Company

CLIENT-PHARMA LTD is a private limited company registered with Companies House under company number 08723939. It was incorporated on 8 Oct 2013. Its status is active. The registered office is in Burton on trent (DE14). Its nature of business (SIC 2007) is wholesale of pharmaceutical goods (46460).

Accounts

The latest accounts in the database are for 2025 (period ending 31 Dec 2025); the company files small company accounts (filleted). Net assets were £2,525,935, up 31.3% on the previous year. Cash at bank and in hand was £1,935,621. Total assets were £3,896,683 and total liabilities £1,368,186. The company had an average of 0 employees. Figures are available for 5 financial years (2020–2025).

Control and charges

2 persons with significant control are registered. 1 of 2 registered charges are outstanding.

Filing deadlines

The next accounts are due by 30 Sep 2027. The next confirmation statement is due by 17 Oct 2026.